Gene · 722
C4BPA: complement component 4 binding protein alpha
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. C4BPA: complement component 4 binding protein alpha. Genes, record 722. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/722
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P04003 | C4b-binding protein alpha chain | 597 | 9 | Ensembl, GeneID, HGNC |
Source UniProt
Patents97
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 42060 | P04003 | Espacenet |
| WO 2025262255 A1 | 2025-12-26 | 28 | P04003 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 8167 | P04003 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 8324 | P04003 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 1905 | P04003 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5687 | P04003 | Espacenet |
| WO 2025184411 A1 | 2025-09-04 | 642 | P04003 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5687 | P04003 | Espacenet |
| EP 4587839 A2 | 2025-07-23 | 52 | P04003 | Espacenet |
| EP 4582098 A2 | 2025-07-09 | 1402 | P04003 | Espacenet |
1 to 10 of 97
See all 97 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,526
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | C4BPA papers | Newest fiscal year |
|---|---|---|---|
| R01DK110023 | C3 Glomerulopathy -- A Collaborative Study | 6 | 2025 |
| T32AR007279 | Immunobiology of the Rheumatic Diseases | 6 | 2025 |
| P20GM103418 | Kansas IDeA Network of Biomedical Research Excellence 5 | 5 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| T32AI007046 | Infectious Diseases Training Program | 5 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 4 | 2025 |
| R01DK076690 | Complement-mediated injury of the kidney: New mechanisms and novel therapies | 4 | 2025 |
| ZIAAI001020 | Host Immune Responses to Antigens of Malaria Parasites | 4 | 2025 |
| ZIAHL006223 | The role of the intracellular complement system - the complosome - in Th1 biology | 4 | 2025 |
| P30EY008126 | Core Grant in Vision Research | 3 | 2025 |
1 to 10 of 1,526Source NIH's project files
See all 1,526 nih grantsPapers2,921
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Treatment-Driven Peripheral Blood Transcriptomic Remodeling and Baseline Predictors of ESSDAI and STAR Response to B Cell Therapy in Sjögren's Disease. | Arthritis Rheumatol | 2026 | 42781881 | PubTator, text mining | PubMed |
| Multi-omics analyses demonstrate complement dysregulation is involved in focal segmental glomerulosclerosis. | Front Immunol | 2026 | 42780117 | PubTator, text mining | PubMed |
| Generation and evaluation of multimers of anti C-reactive protein Nb and alkaline phosphatase based on three self-assembly peptides. | Exp Ther Med | 2026 | 42713007 | PubTator, text mining | PubMed |
| Serum Proteomic Profiling Reveals Renin-Associated Immune and Cytoskeletal Dysregulation in Post-COVID-19 Condition Patients with Secondary Adrenal Insufficiency. | J Proteome Res | 2026 | 42695868 | PubTator, text mining | PubMed |
| Pre-clinical efficacy of a C4BP hexameric IgG Fc fusion protein against Neisseria gonorrhoeae. | PLoS One | 2026 | 42640922 | PubTator, text mining | PubMed |
| Plasma Proteomic Signatures in Alkaptonuria. | Biology (Basel) | 2026 | 42589138 | PubTator, text mining | PubMed |
| DIA-based serum proteomics of the complement-coagulation cascade identifies candidate biomarkers for myasthenia gravis. | Front Neurosci | 2026 | 42516550 | PubTator, text mining | PubMed |
| Association of Endometrial HAND2 Expression with β2-Glycoprotein I Antibodies in Recurrent Pregnancy Loss. | Biomedicines | 2026 | 42512033 | PubTator, text mining | PubMed |
| Glioblastoma immune-related gene landscape and its prognostic significance identified with integrative multiomics. | BMC Cancer | 2026 | 42464188 | PubTator, text mining | PubMed |
| Malondialdehyde epitopes exposed on dying cells are potent modulators of complement activity and efferocytosis. | J Lipid Res | 2026 | 42425490 | PubTator, text mining | PubMed |
1 to 10 of 2,921
See all 2,921 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/722
GET https://conductscience.org/api/genes/v1/722/patents?page=2